IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced a reverse stock split of its issued and outstanding common stock, par ...

IMUNON announces Phase 3 trial for IMNN-001, an immunotherapy showing overall survival benefits in advanced ovarian cancer. Quiver AI Summary. IMUNON, Inc. has announced the initiation of a Phase ...

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025. ASCO 2025 overall survival data bolster IMNN-001’s ...

Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with ...

IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.

IMUNON, Inc. will announce 2024 financial results on February 27, 2025, followed by a conference call for updates. Quiver AI Summary. IMUNON, Inc. has announced that it will report its full year ...

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on ...

Imunon’s stock skyrocketed on massive volume Tuesday, after the biotechnology company announced positive survival data from a trial of its ovarian cancer treatment, IMNN-001.

Imunon Inc. Annual stock financials by MarketWatch. View the latest 0HUZ financial statements, income statements and financial ratios.

Imunon Inc. Annual stock financials by MarketWatch. View the latest IMNN financial statements, income statements and financial ratios.